Characteristics of Dapagliflozin Responders: A Longitudinal, Prospective, Nationwide Dapagliflozin Surveillance Study in Korea
2018 · Diabetes Therapy · 36 citations
https://doi.org/10.1007/s13300-018-0470-9
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
4
Papers
43
Citations
2
h-index
1
i10-index
Ari Kim is an academic researcher from AstraZeneca (South Korea). The author has contributed to research in topics: Diabetes Treatment and Management & Diabetes Management and Research & Medication Adherence and Compliance. The author has an h-index of 2, co-authored 4 publications.
https://doi.org/10.1007/s13300-018-0470-9
https://doi.org/10.1186/s12902-017-0220-4
Click to start Chat